DE-ROCKET.CHAT
22.7.2021 14:02:09 CEST | Business Wire | Press release
Rocket.Chat , the leading open-source communication hub, is announcing the release of Catalyst , its new partner program that consolidates all the assets needed to accelerate growth of new and existing partners across the globe.
“Since the beginning we have been working in close collaboration with service and technology providers to deliver increased value to our customers, which naturally led us to clearly understand the key aspects needed to support our partners’ growth throughout their journey and ultimately leverage their ROI through our partnership. Rocket.Chat’s Catalyst materializes these learnings into a journey-based program that will support companies of all sizes that target the same market and want to establish a results-driven, long-lasting relationship with Rocket.Chat,” said Julio Azzini, Global Head of Partnerships at Rocket.Chat.
The pandemic forced businesses around the globe to abruptly adopt the remote work environment, on a never-before-seen scale. This presented a unique opportunity for Rocket.Chat, helping to boost the company’s hyper growth - a trend that is set to continue as evidence mounts that the remote work momentum will not fade away for the foreseeable future. As an open-source business, Rocket.Chat benefits from a strong global footprint across different sectors that, combined with its recent Series A funding round , will accelerate growth and create opportunities for both Rocket.Chat and its partner ecosystem.
“The investment we made to revamp our existing (partner) program reinforces our commitment to our partners and ultimately, to our customers, to better serve them at a local level and on a global scale. Our partner ecosystem plays a crucial role in our go-to-market strategy,” shared Gabriel Engel, co-founder and CEO of Rocket.Chat. “Partners act as our service arm because they are the ones who are implementing strategic projects, scaling our apps and setting up the integrations that enable our customers to personalize and make the most of their Rocket.Chat experience.”
The new program encompasses a self-paced, scalable onboarding process that enables all key roles within a partner organization to sell and deliver projects through the Rocket.Chat partner portal. The robust capabilities of the program increase collaboration between internal teams and external providers to better manage the partner experience and overall journey while working within Rocket.Chat.
“We decided to implement the same training that we provide to our internal team to our partners. We see our partner relationships as a critical part of our company, rather than just a go-to-market channel. On top of all improvements made we have hired a very talented and competent group of professionals, now outfitted with the assets they need to ensure that we are taking our partner program -- and ultimately our partnerships -- to the next level,” added Azzini.
The new partner program operates across three tiers that are organized based on the overall capabilities and contributions of partners across all types of business models. For more information, please visit: www.Rocket.Chat/partners
About Rocket.Chat
Rocket.Chat is used by Audi, Alfa-Bank, Caixa, Daimler, HTC, Intel, Lockheed Martin, Nationwide Insurance, and other enterprises worldwide to control their communication, manage their data, and have their own collaboration platform to improve team productivity. Rocket.Chat users can switch between team chat and video or audio calls with screen sharing for more efficient teamwork. The platform’s open-source foundation empowers enterprises with complete access to the source code so that they can fully customize, extend or add new functionality to meet their unique requirements. Rocket.Chat is now installed on more than 700,000 servers, counts over 12 million users worldwide, and has an active, passionate community of over 800 developer-contributors who help Rocket.Chat’s core team of developers to constantly improve the product.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210722005172/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom